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Purpose
Concurrent chemoradiotherapy (CCRT) for squamous cell carcinoma of the head and neck
(SCCHN) increases both local tumor control and toxicity. This study evaluates clinical factors that
are associated with and might predict severe late toxicity after CCRT.
Methods
Patients were analyzed from a subset of three previously reported RTOG trials of concurrent
chemoradiotherapy for locally advanced SCCHN (RTOG 91-11; 97-03; and 99-14). Severe late
toxicity was defined in this secondary analysis as chronic Grade 3-4 pharyngeal/laryngeal toxicity
(RTOG/EORTC late toxicity scoring system) and/or requirement for a feeding tube ≥2 years after
registration and/or potential treatment-related death (e.g. pneumonia) within 3 years. Case-control
analysis was performed, with a multivariable logistic regression model that included pre-treatment
and treatment potential factors.
Results
A total of 230 patients were evaluable for this analysis, 99 cases (patients with severe late toxicities)
and 131 controls; thus 43% of evaluable patients had a severe late toxicity. On multivariable analysis,
significant variables correlated with the development of severe late toxicity were older age (odds ratio
1.05 per year; p = 0.001); advanced T-stage (odds ratio 3.07; p=0.0036); larynx/hypopharynx primary
site (odds ratio 4.17; p=0.0041); and neck dissection after chemo-RT (odds ratio 2.39; p=0.018).
Conclusions
Severe late toxicity following CCRT is common. Older age, advanced T-stage, and larynx/
hypopharynx primary site were strong independent risk factors. Neck dissection after CCRT was
associated with an increased risk of these complications.

mucositis, as summarized in a meta-analysis
by Trotti et al.12. Comprehensive data on late
toxicity from randomized trials of RT +/chemotherapy, however, are sparse. Late toxicity
may include long-term severe dysphagia and
its related effects, including dependence upon
a feeding tube, and have a profound effect on
quality of life. The increased incidence of these
serious, potentially permanent effects after
CCRT is concerning, leading some to question
as to whether chemoradiotherapy is truly a
major improvement in the therapeutic ratio
over radiotherapy alone.13
Starting approximately 15 years ago, the RTOG
conducted a series of prospective clinical trials
using CCRT for locally advanced SCCHN.
General data on efficacy and early and subacute
toxicity have been reported14-16. It is likely,
however, that each individual study is
underpowered for a thorough analysis of late
effects, given sample size and patient attrition
due to mortality and other causes. Consequently,
we performed a secondary analysis of severe late
toxicities from these several trials, specifically
focusing on late toxicities and mortality related
to pharyngolaryngeal dysfunction. An analysis
of potential factors associated with severe late
toxicities was undertaken.

Materials/Methods
As noted above, the three prospective trials
analyzed for this paper have been previously reported. All three studies required an
acceptable performance status (60-100% by
Karnofsky scale); non-metastatic stage III/IV
SCCHN; and good hematologic, renal, hepatic
and cardiovascular function.
Briefly, the three studies are:

Background/Introduction
Concurrent chemoradiotherapy (CCRT) is a standard treatment for patients with locally advanced
squamous cell carcinoma of the head and neck (SCCHN) treated non-surgically. Meta-analyses
show an improved 5-year survival by approximately 8% when CCRT is compared to radiotherapy
alone1, 2. The advantage of this approach with respect to disease free survival and local-regional
control is greater than 8%3-6, 7-10.
While there are undisputed advantages to CCRT for local-regional control, it increases toxicity
when compared to radiotherapy alone11. Many studies have focused on acute toxicity, particularly
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RTOG 91-1114: A phase III trial of larynxpreserving radiotherapy or chemoradiotherapy
for selected Stage III/IV larynx cancer. For
this analysis, only the concurrent chemoradiotherapy arm was studied; this treatment
in this arm consisted of 70 Gy in conventionally fractionated radiotherapy (XRT) – 2 Gy
once daily – plus three cycles of high dose

RTOG Analysis

cisplatin (100 mg/m2, Weeks 1, 4, and 7). There were 172 patients in
this arm from RTOG 91-11; 88 patients were evaluable for this analysis
of late toxicity.
RTOG 97-0317: A Phase IIR trial of several novel regimens of concurrent chemoradiotherapy for stage III/IV head and neck cancer (excluding
patients who were eligibile for RTOG 91-11). This study included three
arms. Arms 1 and 3 utilized conventionally fractionated XRT as per 9111. Arm 1 chemotherapy was infusional 5-FU and cisplatin, both given
daily during the last two weeks of XRT. Arm 3 chemotherapy was once
weekly cisplatin (20 mg/m2/week) and paclitaxel (30 mg/m2/week).
Arm 2 chemoradiotherapy was modeled upon the prospective phase
II trials performed by the University of Chicago. In Arm 2, although
the total XRT dose remained 70 Gy in 2 Gy fractions, it was delivered
over 13 weeks (week-on, week-off technique); chemotherapy in Arm 2
consisted of concurrent infusional 5-FU and hydroxyurea. There were
231 patients in RTOG 97-03; 102 patients were evaluable for this analysis
of late toxicity.
RTOG 99-1416: A Phase II trial of accelerated radiotherapy with
concurrent chemotherapy for stage III/IV head and neck cancer. This
single arm phase II study consisted of accelerated concomitant boost
radiotherapy to 72 Gy over 6 weeks (as per the concomitant boost arm of
RTOG 90-03), with two cycles of high dose cisplatin (100 mg/m2 weeks 1
and 4). There were 76 patients in RTOG 99-14; 40 patients were evaluable
for this analysis of late toxicity.
All of these studies used conventional radiotherapy techniques, mostly
2-dimensional planning and delivery. No patient received intensity
modulated radiation therapy (IMRT). For this report, a severe late
toxicity was defined as any or all of the following events:

Statistical Analysis
Frequency tables with counts and percentages were used to describe
pretreatment and treatment characteristics for each group. Univariate
and multivariable logistic regression models were used to identify
associations of pretreatment and treatment-related factors with severe
late toxicity. All models were stratified by the 5 treatment arms described
above. The following factors were studied: age (continuous variable);
gender; race (non-black vs. black); KPS (60-80 vs. 90-100); hemoglobin
(continuous variable); weight loss pre-treatment (continuous variable);
T-stage (T1/2 vs. T3/4); N Stage (Nx/0/1 vs. N2 vs. N3); Tumor site
(oral cavity/oropharynx vs. larynx/hypopharynx); radiotherapy dose
received as assessed by late effects BED model (total RT dose multiplied
by (1+ [dose/fraction size] ÷ 3): continuous variable); chemotherapy
dose received (<85% of planned dose vs. > 85% of planned dose); and
post-RT neck dissection (yes vs. no). Variables’ levels were grouped in
order to avoid small cell counts. A stepwise selection procedure was
used to build the multivariable logistic regression model using the above
pretreatment/treatment variables. Entry criterion was set at p < 0.05.
The odds ratios (OR) for each variable in the final model along with
their 95% confidence intervals and p-values are reported. The odds
ratios estimate how much more (less) likely it is to be in the case group
versus the control group among patients with the specific variable level’s
characteristic compared to those patients in the reference level (RL), after
stratifying for treatment arm. The cumulative incidence method was
used to estimate time to severe late toxicity and levels for pre-treatment/
treatment-related variables were compared using the Gray’s test 18, 19.

Table 1. Summary of Patients Excluded from this Analysis

• Grade 3 or greater toxicity (RTOG/EORTC Late Toxicity Criteria)
present > 180 days after the start of XRT and clearly related to
dysfunction of the larynx and/or pharynx (e.g. dysphagia)
• Requirement for a feeding tube/gastrostomy 2 years or longer after the
start of XRT.
• Death without cancer progression and from an uncertain cause in
which laryngeal dysfunction is suspected to be a contributing factor
(e.g. pneumonia) ≤ 3 years from the date of randomization. Patients
who died of unknown causes were included in this category. Review
of these deaths was performed by one of the study authors (MM) in
a manner blinded to any of the patient’s clinical pre-treatment and/or
treatment related characteristics.
Patients who suffered one or more qualifying severe late toxicity events
were only considered to be one “case.”
Patients with severe laryngopharynx dysfunction due to cancer, prior to
the start of treatment, were excluded because of the potential confounding
nature of tumor destruction of critical normal tissues (See Table 1). In
RTOG 91-11, the determination of severe pre-treatment laryngopharynx
dysfunction was based on patients’ on-study data collection form, which
scored airway obstruction and dysphagia on a 4-point scale (none, mild,
moderate, severe/life-threatening); patients with severe/life-threatening
airway obstruction and/or dysphagia based on this form were excluded.
In RTOG 91-11, data on pre-treatment use of feeding tubes were not
collected. In RTOG 97-03 and RTOG 99-14, pre-treatment feeding tube
data were collected, and this was used as the primary means of defining
patients with pre-treatment severe laryngopharynx dysfunction.
Patients with missing/inevaluable data or early death from acute toxicity
were also excluded.

RTOG 91-11 RTOG 97-03 RTOG 99-14 Total
(Original
(Original
(Original
(Original
N=172)
N=231)
N=76)
N=479)
Reason for Exclusion
Severe Pre-treatment
Airway Obstruction

15

—

—

15

Severe Pre-treatment
Dysphagia

5

—

—

5

Pre-treatment Feeding
Tube Dependence

—

62

18

80

Total Excluded due to
Severe pre-treatment
laryngopharynx
dysfunction

20

62

18

100

2

3

1

6

Tumor Recurrence/
death < 3 yrs followup.

52

62

16

130

Missing Data

10

2

1

13

Grand Total Excluded

84

129

36

249

Total Analyzable
for this study

88

102

40

230

Death from Acute
toxicity

Abbreviations as in Table 4.
Reference level: GTV ≤45 cm3, dose 90.3 Gy.
*Chi-square test using Cox proportional hazards model.
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Case Group
(n=99)

Control Group
(n=131)

Age
Median
Range
Age ≤ 70
Age > 70

60
33-78
85 (86%)
14 (14%)

56
26-78
118 (90%)
13 (10%)

78 (79%)
21 (21%)

99 (76%)
32 (24%)

Non-Black
Black

90 (91%)
9 ( 9%)

120 (92%)
11 ( 8%)

60-80
90-100

24 (24%)
75 (76%)

20 (15%)
111 (85%)

14.3
7.1-18.2
28 (28%)
71 (72%)

14.2
9.9-18.2
43 (33%)
88 (67%)

Gender
Male
.
Female
Race

KPS

Hemoglobin
Median
Range
Hgb ≤ 13.5 gm/dl
Hgb > 13.5 gm/dl

Weight Loss in Previous 6 months (kg)
Mean
3.9
≤ 5 kg
78 (79%)
> 5 kg
21 (21%)
T Stage
T1/T2
T3/T4
N Stage
NX/N0/N1
N2
N3
Tumor Site
Oral cavity/oropharynx
Oral Cavity
Oropharynx
Larynx/hypopharynx
Larynx
Hypopharynx
Radiotherapy Dose-Intensity
delivered (BED)
Mean
Median
Range

18 (18%)
81 (82%)

2.8
112 (86%)
19 (14%)
39 (30%)
92 (70%)

47 (47%)
42 (42%)
10 (10%)

63 (48%)
58 (44%)
10 ( 8%)

Of these 230 patients, 99 patients (cases) had severe late toxicity and
131 patients (controls) did not have severe late toxicity. This results in
a crude rate of late toxicity of 43%. It should be noted that if the entire
population of patients (N=479) from all three studies are analyzed (as is
often performed for studies of late effects) the crude rate would appear
to be 21%., considerably lower than the data reported here. An actuarial
plot of “Time to Severe Late Toxicity” for all 230 evaluable patients is
shown in Figure 1.
100

75

50

25

0
Pts. at Risk
for Case 230

12

24

36

48

60

72

17

11

Months From Randomization
174

143

81

36

Figure 1. Time to Severe Late Toxicity Events – All Evaluable Patients.
42
7
35
57
41
16

(42%)
(7%)
(35%)
(58%)
(41%)
(16%)

115 Gy
117 Gy
67-117 Gy

71
5
66
60
51
9

(54%)
(4%)
(50%)
(46%)
(39%)
(7%)

116 Gy
117 Gy
111-126 Gy

Neck Dissection after RT
Yes
No

26 (26%)*
73 (74%)

21 (16%)
110 (84%)

Chemotherapy dose-intensity
delivered
< 85%
≥ 85%

22 (22%)
77 (78%)

29 (22%)
102 (78%)
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The original, potential patient population from these three studies was
479. However, there were 130 patients excluded because of local-regional
failure or death due to cancer, 100 patients excluded because of severe
pre-treatment laryngopharynx dysfunction due to tumor, 13 patients
excluded because of missing data, and 6 patients excluded because of
early death due to acute toxicity (see Table 1);. Thus, the overall evaluable
sample size for this report was 230 patients. The median followup for the
patient population is 2.96 years.

0

*Two of these patients had their neck dissection after experiencing a severe late toxicity

36

Results

% Failed

Table 2. Summary of patients with severe late toxicities (cases)
and patients without severe late toxicities (controls)

Table 3. Types of late toxicity events seen by trial
91-11
Feeding Tube Dependence
> 2 yrs. Post RT
Grade 3+ Pharyngeal
Dysfunction (RTOG late
toxicity criteria)
Grade 3+ Laryngeal
Dysfunction (RTOG late
toxicity criteria)
Death
Other (e.g. infection, fistula)
Any
No Severe late toxicity
event (controls)

97-03

—*

99-14
29*

Total
29

16

28

19

63

22

6

0

28

9
0
40**
62

2
1
21**
19

11
3
38**
50

* Feeding tube data were not collected at all in RTOG 91-11.
** Numbers do not always add up along columns, due to some patients having more than one
toxicity event.

22
4
99**
13

RTOG Analysis

Figure 2. Time to Severe Late Toxicity Subgoup Analyses based
on Patient/Treatment Characteristics
(All graphs exclude 2 patients who had neck dissection after already
experiencing a severe late toxicity.)

Patients with severe toxicities (cases) were more likely to be older and/or
to have larger T-stage and/or larynx/hypopharynx primary cancer. On
univariate analysis, there were no statistically significant differences in
the rates of late effects based on each individual study/arm.

100

Failed/Total
T1/T2
T3/T4

% Failed

75

17 / 56
80 / 172

50

25

0
0
Pts. at Risk
Case
56
Control 172

12

24

36

48

60

72

2
15

2
9

Months From Randomization
47
127

41
102

27
54

8
28

The pre-treatment characteristics of these 230 patients are shown in Table
2, including both pre-treatment and treatment-related characteristics.
Table 3 shows an accounting of the types of late toxicity events observed
in this analysis; most were related to swallowing function (particularly in
RTOG 97-03 and RTOG 99-14) or laryngeal dysfunction (RTOG 91-11).

Figure 2a. Time to Severe Late Toxicity by T stage Advanced T
stage is associated with a higher likelihood of severe late toxicity
(p value from Gray’s Test =0.031).

Univariate logistic regression analysis of pre-treatment and treatmentrelated variables is shown in Table 4. Actuarial estimates of time to
severe late toxicity as a function of T-stage, primary tumor site, and
neck dissection are shown in Figures 2a to 2c, respectively. The most
significant pre-treatment factor associated with severe late toxicity was
age, analyzed as a continuous variable (p=0.0038) – older patients were
significantly more likely to have severe late toxicity. T-stage (T3-4 more
likely to have severe late toxicity) and tumor site (larynx/hypopharynx
more likely to have severe late toxicity) were also statistically significant
factors. On univariate analysis, none of the treatment-related variables
were statistically significant except BED (p<0.0001), with a paradoxical
negative association between BED and severe late toxicity. The p-value
for potential association between severe late toxicity and neck dissection
after RT was 0.145.
The results of a multivariable logistic regression model analysis are
shown in Table 4. Age, T-stage and tumor site remained statistically
significant. In addition, a positive association between post-treatment
neck dissection and severe late toxicity was noted (p=0.02). Specifically,
out of the 230 patients in this study, 47 (20%) underwent post-treatment
neck dissection; this included 22% of the oral cavity/oropharynx patients
and 19% of the larynx/hypopharynx patients. These 47 patients had a

100

100

Failed/Total
Oral cavity/oropharynx
Larynx/hypopharynx

42 / 113
55 / 115

Yes ND
No ND

75

% Failed

% Failed

75

Failed/Total

50

25

24 / 45
73 / 183

50

25

0

0
0

Pts. at Risk
Case
115
Control 113

12

24

36

48

60

72

Months From Randomization
81
93

64
79

43
38

31
5

17
0

11
0

Figure 2b. Time to Severe Late Toxicity by Primary Tumor Site
Larynx/Hypopharynx cancer is associated with a statistically
non-significant higher likelihood of severe late toxicity (p value
from Gray’s Test =0.076).

0
Pts. at Risk
Case
45
Control 183

12

24

36

48

60

72

3
14

2
9

Months From Randomization
30
144

25
118

15
66

4
32

Figure 2c. Time to Severe Late Toxicity by Neck Dissection
Neck dissection is associated with a statistically non-significant
higher likelihood of severe late toxicity (p-value from Gray’s
Test =0.09).
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Table 4. Univariate and Multivariable Logistic Regression
Models to Identify Covariates that are associated with
severe late toxicity.
Univariate
Analysis

Covariates

Odds
Ratio

p-value

Age
Continuous variable

1.043*

0.0038

Gender
Female
Male

RL
1.140

0.6846

Multivariate
Analysis
95%
Odds confidence
Ratio Interval p value
1.05*

[1.02,1.09]

0.001

crude rate of severe late toxicity of 55% (compared with 40% for the 183
patients who did not undergo neck dissection).
Of note, besides neck dissection, other treatment-related factors were
not associated with severe late effects. Although the most aggressive
radiotherapy fractionation trial (RTOG 99-14, which used concomitant
boost XRT + cisplatin) numerically had the highest crude rate of
severe late toxicity (21/40 = 53%), there were no statistically significant
differences among the trial arms.
As noted in Table 4, radiotherapy dose delivered (as analyzed as
biologically equivalent dose [BED]) was significant on univariate analysis
(with a paradoxical relationship in which lower RT dose was associated
with higher risk) but fell out of the multivariable model. The amount of
chemotherapy delivered was not statistically significant in either model.

Discussion
Race
Non-Black
Black

RL
1.165

KPS
60-80
90-100

1.892
RL

0.0612

Hemoglobin (gm%)
Continuous Variable

1.005

0.9528

Weight loss (kg)
Continuous Variable

1.018

0.3733

T Stage
T1/T2
T3/T4

RL
2.041

0.0349

N Stage
NX/N0/N1
N2
N3

0.7458

RL
0.942
1.297

0.8464
0.6108

Tumor Site
Oral cavity/oropharynx RL
Larynx/hypopharynx 2.955

0.0131

BED (Toxicities)
based on Actual
Dose/Fx (Gy)
Continuous Variable

0.842

Neck dissection after RT**
Yes
1.632
No
RL
Percent of chemotherapy
received relative to the
protocol amount
< 85%
1.033
≥ 85%
RL

RL
3.07

RL
4.17

[1.444,6.54] 0.0036

[1.57,11.03] 0.0041

<0.0001

0.145

2.39
RL

[1.16,4.92]

0.018

0.9216

Abbreviations: RL=reference level; RT=radiation therapy
* The odds ratio of 1.043 for age indicates that for each one year increase in age, patients have 1.043 times
higher odds of being in the case group (having a severe late toxicity) than being in the control group (not
having a severe late toxicity).
** This excludes 2 patients who had neck dissection after having already experiencing a severe late toxicity.
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This retrospective analysis of several prospective trials shows that the rate
of severe late toxicity after CCRT for SCCHN is high, particularly with
the analysis methodology used here. Specifically, in this study, patients
with severe pre-treatment laryngopharynx dysfunction and patients
with early tumor recurrence were excluded a priori from this analysis.
Thus, the number of patients “at risk” for a severe late toxicity event
is much smaller than the original treated population. This technique
closely approximates the use of actuarial analysis of late complications,
a technique which yields a higher rate of complications than simply
reporting crude rate of complications, as reported by Bentzen et al.20
A true actuarial analysis of late complications in head and neck cancer
is difficult, because it is not easy to ascertain a date of onset of a late
complication in any one individual patient (Figures 2a-2c). Our sample
size of 230 patients makes this one of the largest studies of late toxicity in
the concurrent chemoradiotherapy era.
In this study, several factors that correlated with severe late toxicity were
identified. Since this is a retrospective study, the data must be considered
hypothesis-generating rather than definitive. Some caveats result from
the fact that these studies were conducted over a 10-year time period
(approximately 1991-2001), with variations in eligibility, treatment, and
data collection techniques. A second problem inherent to retrospective
studies like ours is that a number of potentially important factors may
not have been collected at all. For example our database does not include
information on tumor volume, cardiopulmonary co-morbidity, and
amount of tobacco consumed in followup.
However, it is logical to believe that age, tumor site and tumor stage
would predict for greater likelihood of severe late toxicity. The finding
that post-treatment neck dissection was significantly associated with
severe late toxicity was somewhat more surprising, although this has
been reported previously. The number of patients undergoing posttreatment neck dissection was relatively small (20%, despite over 50%
of the patients having N2-3 disease), and thus these data can not be
considered conclusive. It is possible that selection bias could lead to this
association; for example, patients with larger volume neck disease may
be more likely to undergo neck dissection and may be more likely to
have neck-tumor-related damage to adjacent normal tissues unrelated
to the neck dissection. It is possible, though, that disturbance of the soft
tissues of the neck via post-treatment neck dissection could cause added
swallowing dysfunction, for example by increasing fibrosis in the neck
and thus limiting the mobility of the laryngopharynx. It should be noted
that a similar report of an association between severe late toxicity and
post-treatment neck dissection was recently reported by researchers at

RTOG Analysis

Fox Chase Cancer Center21. If these findings are validated in additional,
larger datasets, there may be important implications with respect to the
controversy regarding neck dissection following chemoradiotherapy for
patients with advanced neck disease.
The lack of significant association between cumulative radiotherapy dose
delivery (or chemotherapy dose delivery) and severe late toxicity may
be due to the narrow dose range prescribed and the generally excellent
compliance. We are currently analyzing the detailed radiotherapy
records (simulation films, dosimetry and treatment records) available at
RTOG headquarters in order to estimate the doses received by individual
normal tissue sub-structures within the head and neck. Several recent
single-institution studies have rigorously analyzed the relationships
between radiotherapy dose-volume-histograms for normal structures
and the risk and severity of toxicities22, 23.
Considering the widespread acceptance of CCRT for SCCHN over the
last 10 years, there are relatively few detailed studies of late toxicities.
GORTEC reported long-term followup from their randomized trial of
radiotherapy alone versus 5-FU/carboplatin/radiotherapy for oropharynx
cancer; they did not find a significant difference in severe late toxicity24.
However, there were fewer than 50 long-term survivors in that study.
Staar reported that 51% of long-term survivors (> 2 years) after a very
intense combination of accelerated fractionation radiotherapy and
chemotherapy were dependent on feeding tubes8. With longer followup,
that alarmingly high rate did decrease, and was not significantly worse
than accelerated radiotherapy alone but the number of evaluable patients
was relatively small25. Shiley reported that 4 of 13 (31%) cancer-free
survivors (>1 year) after chemoradiotherapy required tube feedings for
some or all of their nutrition26.
These data suggest that the CCRT has reached the limits of acceptable
long-term toxicity. Dose intensity can not be easily increased without
some new and effective technique(s) of protection against late effects.
In the future, these may include modern techniques in radiotherapy
technology27, 28, or biopharmacologic radioprotectors29-31. Presently,
however, these techniques have only succeeded in reducing xerostomia,
not severe late dysphagia. Emphasis should therefore be on careful
patient selection for aggressive treatment and swallowing exercises before
during and after radiotherapy32, 33. Some patients may benefit from more
invasive procedures, such as dilatation of hypopharyngeal/esophageal
stricture under anesthesia.
For some patient subpopulations the risks of concurrent chemoradiotherapy may outweigh the benefits. For example, subgroup analysis of a
meta-analysis suggested that there was no significant survival benefit to
CCRT in patients older than age 701. Our data may add to the controversy
regarding management of the elderly patient with head and neck cancer
– if there is no significant survival benefit and a significant increase in
late toxicity with concurrent chemoradiotherapy, should it be the standard of care in this patient population?
Our study has several limitations that should be discussed. First, it is
a “meta-analysis” of three separate clinical trials, each of which had
somewhat different eligibility criteria, chemoradiotherapy regimen, and
year of activation. However, all of the patients did receive treatment that
would be considered appropriate standard of care in today’s oncology
clinic. Second, our exclusion of patients with pre-existing severe
laryngopharynx dysfunction from this analysis can be considered
controversial. Although patients were excluded a priori, determining
pre-existing severe laryngopharynx dysfunction is subjective. However,
it should be noted that the determination of post-treatment severe

laryngopharynx dysfunction (toxicity) is also subjective. It is extremely
difficult to determine if severe dysfunction after treatment is the result of
treatment or the result of the pre-existing cancer. By excluding patients
with pre-treatment severe laryngopharynx dysfunction, we attempted to
isolate the influence of treatment on outcomes. Third, our study is an
exploratory analysis; while it is one of the larger series on late toxicity
after chemoradiotherapy, the number of patients and number of events
are relatively small. We plan to address this in the future with an analysis
of the recently completed trial, RTOG 0129. This was a randomized trial
of standard fractionation versus accelerated fractionation radiotherapy
(with cisplatin in both arms). Preliminary acute and subacute toxicity
data showed no significant differences between the two arms34. It is
premature at this time to perform a detailed analysis of efficacy or late
toxicity from that study. It is possible that with improved knowledge
and experience with CCRT and supportive care available in the 21st
century, outcomes may be improved in RTOG 0129 compared to
historical controls.
Ultimately, it should be remembered that for most patients with head
and neck cancer, the highest priority is cure and length of survival35.
Excessive concern about treatment toxicity should not prevent the use of
proven aggressive multimodality treatment, provided the patient is well
informed about the potential late sequelae of these aggressive treatment
regimens.
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